| Dr Jonathan E Amick, DO | |
|
310 Sunnyview Ln, Kalispell, MT 59901-3129 | |
| (406) 752-5111 | |
| Not Available |
| Full Name | Dr Jonathan E Amick |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 21 Years |
| Location | 310 Sunnyview Ln, Kalispell, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770786154 | NPI | - | NPPES |
| OS013906 | Other | PA | OSTEOPATHIC LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | OS013906 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Valley Hospital | Whitefish, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Logan Health - Whitefish | 9335033687 | 43 |
News Archive
Reports from a case series study indicate that patients with major depression have high rates of treatment-resistant, residual insomnia, and that insomnia during the early remission phase could lead to recurrence of depressive episodes.
It is known that doctors are generally less likely to diagnose depression in men than in women. Little research has been undertaken to explore the reasons for this in rural settings, or to compare GPs' and male patients' assessments of perceived depression.
Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide, which if approved would be administered as a single daily injection for the treatment of adults with type 2 diabetes.
It is still unknown why the natural history of chronic disease caused by hepatitis C virus (HCV), which currently infects 3% of the world's population, varies from mild in some patients to rapidly progressing in others. Age, sex, alcohol consumption and liver sensitivity to gut-derived bacterial endotoxins, were the early factors defined to enhance the risk of fibrosis progression.
Bristol-Myers Squibb has pleaded guilty to two counts of violating 18 U.S.C. Sec. 1001 in U.S. District Court for the District of Columbia. This guilty plea resolved as to the company the previously disclosed investigation by the Antitrust Division of the U.S. Department of Justice into the proposed settlement of the Plavix patent litigation with Apotex Inc., and Apotex Corp. (Apotex).
› Verified 6 days ago
| Entity Name | Logan Health - Whitefish |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396710851 PECOS PAC ID: 9335033687 Enrollment ID: O20040209001144 |
News Archive
Reports from a case series study indicate that patients with major depression have high rates of treatment-resistant, residual insomnia, and that insomnia during the early remission phase could lead to recurrence of depressive episodes.
It is known that doctors are generally less likely to diagnose depression in men than in women. Little research has been undertaken to explore the reasons for this in rural settings, or to compare GPs' and male patients' assessments of perceived depression.
Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide, which if approved would be administered as a single daily injection for the treatment of adults with type 2 diabetes.
It is still unknown why the natural history of chronic disease caused by hepatitis C virus (HCV), which currently infects 3% of the world's population, varies from mild in some patients to rapidly progressing in others. Age, sex, alcohol consumption and liver sensitivity to gut-derived bacterial endotoxins, were the early factors defined to enhance the risk of fibrosis progression.
Bristol-Myers Squibb has pleaded guilty to two counts of violating 18 U.S.C. Sec. 1001 in U.S. District Court for the District of Columbia. This guilty plea resolved as to the company the previously disclosed investigation by the Antitrust Division of the U.S. Department of Justice into the proposed settlement of the Plavix patent litigation with Apotex Inc., and Apotex Corp. (Apotex).
› Verified 6 days ago
| Entity Name | Northern Rockies Anesthesia Consultants Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912930199 PECOS PAC ID: 8022900208 Enrollment ID: O20040325000449 |
News Archive
Reports from a case series study indicate that patients with major depression have high rates of treatment-resistant, residual insomnia, and that insomnia during the early remission phase could lead to recurrence of depressive episodes.
It is known that doctors are generally less likely to diagnose depression in men than in women. Little research has been undertaken to explore the reasons for this in rural settings, or to compare GPs' and male patients' assessments of perceived depression.
Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide, which if approved would be administered as a single daily injection for the treatment of adults with type 2 diabetes.
It is still unknown why the natural history of chronic disease caused by hepatitis C virus (HCV), which currently infects 3% of the world's population, varies from mild in some patients to rapidly progressing in others. Age, sex, alcohol consumption and liver sensitivity to gut-derived bacterial endotoxins, were the early factors defined to enhance the risk of fibrosis progression.
Bristol-Myers Squibb has pleaded guilty to two counts of violating 18 U.S.C. Sec. 1001 in U.S. District Court for the District of Columbia. This guilty plea resolved as to the company the previously disclosed investigation by the Antitrust Division of the U.S. Department of Justice into the proposed settlement of the Plavix patent litigation with Apotex Inc., and Apotex Corp. (Apotex).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jonathan E Amick, DO Po Box 24823, Seattle, WA 98124-0823 Ph: (425) 407-1500 | Dr Jonathan E Amick, DO 310 Sunnyview Ln, Kalispell, MT 59901-3129 Ph: (406) 752-5111 |
News Archive
Reports from a case series study indicate that patients with major depression have high rates of treatment-resistant, residual insomnia, and that insomnia during the early remission phase could lead to recurrence of depressive episodes.
It is known that doctors are generally less likely to diagnose depression in men than in women. Little research has been undertaken to explore the reasons for this in rural settings, or to compare GPs' and male patients' assessments of perceived depression.
Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide, which if approved would be administered as a single daily injection for the treatment of adults with type 2 diabetes.
It is still unknown why the natural history of chronic disease caused by hepatitis C virus (HCV), which currently infects 3% of the world's population, varies from mild in some patients to rapidly progressing in others. Age, sex, alcohol consumption and liver sensitivity to gut-derived bacterial endotoxins, were the early factors defined to enhance the risk of fibrosis progression.
Bristol-Myers Squibb has pleaded guilty to two counts of violating 18 U.S.C. Sec. 1001 in U.S. District Court for the District of Columbia. This guilty plea resolved as to the company the previously disclosed investigation by the Antitrust Division of the U.S. Department of Justice into the proposed settlement of the Plavix patent litigation with Apotex Inc., and Apotex Corp. (Apotex).
› Verified 6 days ago
Kenyon W Kruse, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 310 Sunnyview Ln, Kalispell, MT 59901 Phone: 406-752-5111 | |
Dr. Katherine W Holley, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 310 Sunnyview Ln, Kalispell, MT 59901 Phone: 406-752-5111 | |
Dr. Melanie Pittard, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 310 Sunnyview Ln, Kalispell, MT 59901 Phone: 425-407-1500 | |
Dr. Andrew Francis Palmer, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 310 Sunnyview Ln, Kalispell, MT 59901 Phone: 406-752-5111 | |
Bradford L. Olson, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 310 Sunnyview Ln, Kalispell, MT 59901 Phone: 406-752-5111 | |
Michael A. Sugarman, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 310 Sunnyview Ln, Kalispell, MT 59901 Phone: 406-752-5111 | |
Kevin Jude Scholten, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 310 Sunnyview Ln, Kalispell, MT 59901 Phone: 406-752-5111 |